Corvus Pharmaceuticals, Inc. (CRVS)
10.53
-0.12
(-1.13%)
USD |
NASDAQ |
Oct 23, 16:00
10.50
-0.03
(-0.28%)
After-Hours: 20:00
Corvus Pharmaceuticals Enterprise Value : 671.29M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 671.29M |
| October 22, 2026 | 681.39M |
| October 21, 2026 | 630.92M |
| October 20, 2026 | 646.06M |
| October 19, 2026 | 597.27M |
| October 16, 2026 | 586.33M |
| October 15, 2026 | 614.09M |
| October 14, 2026 | 574.55M |
| October 13, 2026 | 577.08M |
| October 12, 2026 | 630.92M |
| October 09, 2026 | 670.45M |
| October 08, 2026 | 644.37M |
| October 07, 2026 | 661.20M |
| October 06, 2026 | 673.82M |
| October 05, 2026 | 688.96M |
| October 02, 2026 | 702.42M |
| October 01, 2026 | 704.94M |
| September 30, 2026 | 754.57M |
| September 29, 2026 | 774.76M |
| September 28, 2026 | 784.02M |
| September 25, 2026 | 762.98M |
| September 24, 2026 | 778.13M |
| September 23, 2026 | 840.38M |
| September 22, 2026 | 916.08M |
| September 21, 2026 | 830.28M |
| Date | Value |
|---|---|
| September 18, 2026 | 842.06M |
| September 17, 2026 | 841.22M |
| September 16, 2026 | 814.30M |
| September 15, 2026 | 874.87M |
| September 14, 2026 | 888.32M |
| September 11, 2026 | 871.50M |
| September 10, 2026 | 874.02M |
| September 09, 2026 | 906.83M |
| September 08, 2026 | 957.30M |
| September 04, 2026 | 996.00M |
| September 03, 2026 | 1.018B |
| September 02, 2026 | 980.02M |
| September 01, 2026 | 985.91M |
| August 31, 2026 | 966.56M |
| August 28, 2026 | 976.65M |
| August 27, 2026 | 1.024B |
| August 26, 2026 | 1.025B |
| August 25, 2026 | 1.010B |
| August 24, 2026 | 970.76M |
| August 21, 2026 | 1.002B |
| August 20, 2026 | 990.95M |
| August 19, 2026 | 1.081B |
| August 18, 2026 | 1.033B |
| August 17, 2026 | 1.040B |
| August 14, 2026 | 1.038B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.96M |
| Total Expenses (Quarterly) | 17.96M |
| EPS Diluted (Quarterly) | -0.1944 |
| Earnings Yield | -5.87% |
| Normalized Earnings Yield | -5.866 |